Paysign, Inc. (PAYS)
| Market Cap | 853.71M +203.6% |
| Revenue (ttm) | 100.64M +46.8% |
| Net Income | 15.77M +132.5% |
| EPS | 0.26 +115.7% |
| Shares Out | 56.46M |
| PE Ratio | 58.44 |
| Forward PE | 41.52 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 571,213 |
| Open | 14.46 |
| Previous Close | 14.40 |
| Day's Range | 14.15 - 15.36 |
| 52-Week Range | 3.08 - 16.16 |
| Beta | 0.83 |
| Analysts | Strong Buy |
| Price Target | 14.10 (-6.75%) |
| Earnings Date | Nov 9, 2026 |
About PAYS
Paysign, Inc. provides prepaid card programs, patient affordability offerings, digital banking, life science software technology solutions, and integrated payment processing services for businesses, consumers, and government institutions in the United States. The company offers solutions for corporate rewards, prepaid gift cards, general-purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts a... [Read more]
Financial Performance
In 2025, Paysign's revenue was $82.03 million, an increase of 40.50% compared to the previous year's $58.38 million. Earnings were $7.55 million, an increase of 97.90%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for PAYS stock is "Strong Buy." The 12-month stock price target is $14.1, which is a decrease of -6.75% from the latest price.
News
Paysign to Host Third Quarter 2026 Earnings Call
HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated p...
Paysign price target raised to $15 from $12 at DA Davidson
DA Davidson raised the firm’s price target on Paysign (PAYS) to $15 from $12 and keeps a Buy rating on the shares. After digging further into the Patient Affordability niche…
Paysign price target raised to $15 from $13 at Lake Street
Lake Street raised the firm’s price target on Paysign (PAYS) to $15 from $13 and keeps a Buy rating on the shares. After having hosted Paysign at the firm’s BIG10…
Paysign Transcript: 17th Annual Midwest IDEAS Conference
The company operates leading plasma payments and pharma co-pay businesses, achieving strong double-digit revenue and margin growth. Patient affordability programs are expanding rapidly, with significant cost savings for clients and a robust pipeline. Plasma payments remain a cash-generating core, funding further growth.
Paysign, Inc. to Present at the 17th Annual Midwest IDEAS Investor Conference
HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated p...
Paysign Slides: Investor presentation
Paysign has posted slides in relation to its latest quarterly earnings report, which was published on August 17, 2026.
Paysign price target raised to $15 from $11 at Barrington
Barrington analyst Gary Prestopino raised the firm’s price target on Paysign (PAYS) to $15 from $11 and keeps an Outperform rating on the shares. The company reported a better than…
Paysign Slides: Corporate presentation
Paysign has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
Paysign price target raised to $12 from $9 at DA Davidson
DA Davidson raised the firm’s price target on Paysign (PAYS) to $12 from $9 and keeps a Buy rating on the shares.
Paysign price target raised to $13 from $11 at Lake Street
Lake Street analyst Jacob Stephan raised the firm’s price target on Paysign (PAYS) to $13 from $11 and keeps a Buy rating on the shares. Q2 marked “another step-change in…
Paysign raises FY26 EPS view to 57c-61c from 21c-26c, consensus 33c
Raises FY26 revenue view to $114M-$117M from $106.5M-$110.5M, consensus $108.55M.
Paysign Earnings Call Transcript: Q2 2026
Record Q2 results with 48% revenue growth and 113% higher adjusted EBITDA, driven by Patient Affordability and plasma recovery. Full-year guidance raised, margins expanded, and platform scalability demonstrated by rapid program launches and strong win rates.
Paysign Earnings release: Q2 2026
Paysign released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Paysign Quarterly report: Q2 2026
Paysign has published its Q2 2026 quarterly earnings report on August 5, 2026.
Paysign reports Q2 adjusted EPS 16c, consensus 8c
Reports Q2 revenue $28.25M, consensus $26.36M. “Paysign (PAYS) delivered a strong second quarter, achieving record revenue, net income, and adjusted EBITDA while continuing to expand margins,” said Ma...
Paysign sees Q3 adjusted EPS 15c-16c, consensus 7c
Sees Q3 revenue $28.5M-$30M, consensus $26.98M.
Paysign Reports Record Second Quarter 2026 Revenue of $28.3 Million, Up 48%; Raises Full-Year Outlook
HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive pharma patient affordability offerings, financial technology products and int...
Paysign participates in a conference call with DA Davidson
Analyst Heckmann holds a conference call with management on August 12 at 11 am hosted by DA Davidson.
Paysign price target raised to $11 from $8-$9 at Barrington
Barrington raised the firm’s price target on Paysign (PAYS) to $11 from $8-$9 and keeps an Outperform rating on the shares ahead of the Q2 report on August 5. Paysign…
Paysign to Host Second Quarter 2026 Earnings Call
HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated p...
Paysign Transcript: Planet MicroCap Las Vegas 2026
Strong revenue and EBITDA growth driven by both plasma and patient affordability businesses, with proprietary technology providing a competitive edge and significant cost savings for clients. Market leadership, regulatory compliance, and a scalable platform position the company for continued expansion.
Paysign Slides: FY 2026
Paysign has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 17, 2026.
Paysign Transcript: 16th Annual East Coast IDEAS Conference
A leading provider of plasma donor payments and pharma co-pay solutions, the company is experiencing rapid growth in its patient affordability business, driving margin expansion and a shift in revenue mix. Proprietary technology and regulatory compliance underpin its competitive edge.
Paysign Slides: 16th Annual East Coast IDEAS Conference
Paysign has posted slides in relation to its latest quarterly earnings report, which was published on June 11, 2026.
Paysign management to meet with Lake Street
Meeting to be held in Las Vegas on June 16 hosted by Lake Street.